Recent News
DEC 16, 2020
NOV 24, 2020
NOV 16, 2020
OCT 20, 2020
Abpro Announces Initiation of Phase 2/3 Registrational Studies of its Neutralizing Antibody Therapeutic ABP 300 for the Treatment of COVID-19
Abpro Expands Scientific Advisory Board with the Addition of Infectious Disease Leaders
Abpro Announces Peer-Reviewed Publication Demonstrating Efficacy of its Neutralizing Antibody Therapeutic Against COVID-19
Abpro Announces Completion of Dosing in Phase 1 Study of its Neutralizing Antibody Therapeutic, ABP 300 for Treatment of COVID-19
Careers
Abpro offers competitive salaries and generous benefits with the opportunity to learn and grow in an employee-driven culture. We are seeking individuals with infectious enthusiasm, passion, and conviction who will be committed to our core values and mission. If you thrive in an upbeat, energetic, collaborative environment where every individual counts, we are looking for you!